Celltrion bringing original drug Zymfentra to U.S. market
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Celltrion is aiming for another big leap with the debut of Zymfentra, an autoimmune disease treatment, in the U.S. market.
It is the Korean company's first original drug to get approval from the U.S. Food and Drug Administration.
Celltrion said on Monday that Zymfentra, a subcutaneous injection formulation of its infliximab Remsima, was introduced in the U.S. market last week as a treatment for people living with ulcerative colitis or Crohn's disease.
The recommended dosage of Zymfentra is 120 milligrams every two weeks. The wholesale price of the drug has been set at approximately $6,181 for two doses based on a four-week course.
Celltrion aims to log revenues of 1 trillion won ($750 million) with Zymfentra by 2025 by reaching more than 10 percent of its target patients.
The launch is meaningful in that it is the first original drug developed by Celltrion, a company that has focused on biosimilars so far.
"With Zymfentra, Celltrion will accelerate to become a global biopharmaceutical company that does both new drug development and biosimilars," Celltrion founder and chairman Seo Jung-jin said during a press conference in October.
Celltrion is also in talks with various U.S. pharmacy benefit managers (PBMs) to get "preferred drug" status in the second quarter.
PBMs, third-party companies that function as intermediaries between insurance providers and pharmaceutical manufacturers, create lists of prescription medications covered by health insurance plans called formularies, negotiate rebates with manufacturers, process claims and occasionally manage mail-order specialty pharmacies.
The U.S. market for inflammatory bowel disease treatment, the target for Zymfentra, is valued at 12.8 trillion won, according to data from healthcare researcher IQVIA.
"Compared to Remsima SC in Europe, the net sales price is two or three times higher for Zymfentra, resulting in a very favorable cost ratio," said researcher Park Pyeong-kuk from NH Investment & Securities. "Considering the possibility of Zymfentra being listed by large U.S. PBMs in the second quarter, robust profit expansion is forecast starting from the fourth quarter."
Celltrion last year merged with Celltrion Healthcare three years after its original plan was announced. Celltrion Pharm will merge with Celltrion this year, according to Seo.
Celltrion aims to generate 12 trillion won in revenue by 2030, with around 5 trillion won coming from original drugs. The company currently has six biosimilar products, and aims to increase that number to 22 by 2030.
Celltrion shares closed at 182,500 won Monday, up 1 percent from the previous trading day.
BY SARAH CHEA [chea.sarah@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- Super Junior-D&E cancels performances after 'derogatory' song sparks backlash
- Korea may surpass Singapore to become Asia's fifth largest data center market, expert says
- LA Dodgers beat Kiwoom Heroes 14-3 in Seoul exhibition game opener
- Dodgers and Padres in Seoul: Here's what you need to know
- Han So-hee admits dating Ryu Jun-yeol
- San Diego Padres beat Team Korea 1-0 in exhibition pitchers' duel
- [단독] LG엔솔·포스코가 투자한 QPM… “니켈ㆍ코발트 공급 3년 연기”
- Seoul gets Dodgers fever as MLB exhibition games begin
- Le Sserafim's Huh Yun-jin under fire for drinking 'pro-Israel' Starbucks
- North Korea fires unspecified ballistic missile toward East Sea